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Abstract
Alcohol and tobacco consumption are well recognized risk factors for head and neck cancer
(HNC). Evidence suggests that genetic predisposition may also play a role. Only a few
epidemiologic studies, however, have considered the relation between HNC risk and family
history of HNC and other cancers. We pooled individual- level data across 12 case-control studies
including 8,967 HNC cases and 13,627 controls. We obtained pooled odds ratios (OR) using fixed
and random effect models, and adjusting for potential confounding factors. All statistical tests
were two-sided. A family history of HNC in first-degree relatives increased the risk of HNC
(OR=1.7, 95% confidence interval, CI, 1.2-2.3). The risk was higher when the affected relative
was a sibling (OR=2.2, 95% CI 1.6-3.1) rather than a parent (OR=1.5, 95% CI 1.1-1.8), and for
more distal HNC anatomic sites (hypopharynx and larynx). The risk was also higher, or limited to,
subjects exposed to tobacco. The OR rose to 7.2 (95% CI 5.5-9.5) among subjects with family
history, who were alcohol and tobacco users. A weak but significant association (OR=1.1, 95% CI
1.0-1.2) emerged for family history of other tobacco-related neoplasms, particularly with laryngeal
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cancer (OR=1.3, 95% CI 1.1-1.5). No association was observed for family history of non-tobacco
related neoplasms and the risk of HNC (OR=1.0, 95% CI 0.9-1.1). Familial factors play a role in
the etiology of HNC. In both subjects with and without family history of HNC, avoidance of
tobacco and alcohol exposure may be the best way to avoid HNC.
Keywords
Head and neck cancer; family history; pooled analysis; tobacco; alcohol
INTRODUCTION
There is ample variation worldwide in incidence and mortality of cancers of the oral cavity,
pharynx and larynx (head and neck cancers, HNCs), with high rates being observed in some
areas of Europe, North and South America (1) Also within countries, substantial changes in
rates have been observed over time (2;3). These geographical and temporal variations are
mainly attributable to different exposure to alcohol and tobacco, which are the major
determinants of HNCs in high-resource countries (4), and together account for over 75% of
cases in those areas (5;6).
In spite of well-identified lifestyle factors, there are indications that genetic susceptibility
also plays a role in the development in HNCs (7-9) as for many other cancer sites (10).
Familial aggregation may be an indicator of inherited susceptibility. A few epidemiologic
studies considered the risk of HNC in relatives of affected individuals (11-20). The
quantification of the risk remains, however, uncertain. Data are sparse and inconclusive
about whether the risk varies according to head and neck subsite, age and sex of the proband
or of the relative, the type of relative affected and whether a family history of non-HNCs
also affects HNC risk. Very limited data are available on the combined effect of family
history, and tobacco and alcohol exposure (18), (20).
The International Head and Neck Cancer Epidemiology (INHANCE) Consortium (http://
inhance.iarc.fr/) was established in 2004, based on the collaboration of research groups
leading large, molecular epidemiology studies of head and neck cancer that are on-going or
have been recently completed. The consortium was established with the primary goal to
address research questions that are difficult to answer in individual studies, many of which
involve 500 to 1000 cases and a comparable number of controls. The INHANCE database
thus provides a unique opportunity to investigate the role of family history on risk of HNCs.
The goal of the present study was to investigate the association between various aspects of
family history of HNC and other cancers and the risk of HNC, also in combination with
alcohol and tobacco use.
MATERIAL AND METHODS
In the version 1.0 of the INHANCE pooled data, 15 individual case-control studies,
comprising 10,302 head and neck cancer cases and 15,329 controls were included, of which
12 studies (9025 cases and 13739 controls) had information about the family history of
cancer (21-30). Subjects with missing data on age, sex, or race/ethnicity, and cases with
missing information on the site of origin of their cancer were excluded (58 cases and 102
controls), thus the data for this analysis included 8,967 head and neck cancer cases and
13,627 controls.
Characteristics of the individual studies included in the consortium are provided in Table 1
and in a previous article (4). Most were hospital-based case-control studies; all studies
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frequency matched the controls to cases (i.e., no individual matching) on age, sex and
additional factors. Interviews in all studies were conducted face-to-face. Questionnaires
were collected from all the individual studies to assess the comparability of the data and
wording of interview questions. Data from individual studies were received at IARC with
personal identifiers removed. Each data item was checked for illogical or missing values.
Queries were sent to investigators and inconsistencies were resolved.
Cases were subjects with invasive tumors of the oral cavity (lip, tongue, gum, floor of mouth
and hard palate; ICD10 codes C00.3-C00.9, C02.0-C02.3, C03, C04, C05.0, C06),
oropharynx (base of tongue, lingual tonsil, soft palate, uvula, tonsil and oropharynx; ICD10
codes C01, C02,4, C05.1, C05.2, C09 and C10), hypopharynx (pyriform sinus and
hypopharynx; ICD10 codes C12 and C13) oral cavity or pharynx not otherwise specified
(NOS including overlapping sites (ICD10 codes C02.8, C02.9, C05.8, C05.9, C14), larynx
(glottis, supraglottis, subglottis; ICD10 codes C32), or head and neck cancer unspecified.
Cancers of the external lip (ICD10 codes C00.1-C00.2) salivary gland (ICD10 codes C07-
C08) or nasopharynx (C11) were excluded due to the different etiologic pattern (31).(32) In
the overall dataset there was a total of 2332 oral cases, 2922 pharyngeal cases (668
hypopharynx and 2254 oropharynx), 835 unspecified oral/pharynx cases, 2572 laryngeal
cases and 306 overlapping head and neck cases.
Three studies restricted case eligibility to squamous cell carcinomas (SCC) (North Carolina,
Tampa, & Houston). For other studies which provided the ICD-O-2 or ICD-O-3 histological
coding for each tumor (Switzerland, Central Europe, Los Angeles, Puerto Rico, South
America and all but four centers in the International multicenter study), SCC are defined as
histologies 805-808 and malign behavior code (/3). For the Milan, Aviano, Italy multicenter
studies and four centers in the International multicenter study (Bangalore, Madras, and
Trivandrum in India and Khartoum in Sudan), no data were available on histological type.
Of the 6,307 head and neck cancer cases for which histological information was available,
6,069 were squamous cell carcinomas (96.2%). In this analysis, we included all available
cases.
Three categories of cancers in family members were considered:
- Head and neck cancers including only cancers with topography previously described
in the methods section of this paper.
- Other tobacco related cancers (33) (lung (C34), nasopharynx (C11), nasal cavity
(C30), paranasal sinuses (C31), esophagus (C15), stomach (C16), pancreas (C25), liver
(C22), kidney (body and pelvis) (C64), urinary bladder (C67), uterine cervix (C53) and
bone marrow (myeloid leukemia, C92).
- All other cancers.
We used the definitions of smoking of cigarettes, pipes and cigars and alcohol drinking
categories adopted in a previous paper, where a detailed description on the method used for
pooling data on smoking and alcohol across different studies is also provided
(4a)..Information on smokeless tobacco use was collected in some studies only, as its
prevalence of use was negligible in several geographic areas.
Information on family history included the number of brothers and sisters, the number of
first degree relatives (parent, siblings and children) with a history of cancer, the site of the
cancer and the type of affected relative. For the study from Milan (21), information was
available only for a history of HNCs, and not for the number or type of relatives affected,
while for Aviano (22) the information available was if a parent and/or siblings were
affected, but not the sex of the relative. The definition of HNC for first degree relatives
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included malignant neoplasm with ICD9 codes 161 (larynx) and 140-149 (lip, oral cavity
and pharynx), except ICD codes 140.0, 140.1 and 140.9 (lip, vermillion border) and 147
(nasopharynx). We considered a subject to have a family history for a given cancer site if the
subject reported at least one affected first degree relative.
Statistical Analysis
For subjects with missing education level (326 cases and 252 controls), we applied multiple
imputation (5 imputations) with the PROC MI procedure in SAS. We used the logistic
regression model (34a) to predict education level with age, sex, race/ethnicity, study, and
case/control status within each geographic region.
We assessed the associations between head and neck cancer and family history of cancer by
estimating odds ratios (OR) and 95% confidence intervals (CI). First, we obtained study
specific estimates by means of unconditional logistic regression models (35). The models
included age, sex, education, race/ethnicity and packyears of cigarette smoking
(continuous), years of cigar smoking (continuous), years of pipe smoking (continuous),
smokeless tobacco (snuff or chewing tobacco) use (ever/never), number of alcoholic drinks
per day, and number of brothers and sisters. Pooled ORs were estimated with fixed effects
unconditional logistic regression models, adjusted for all the factors mentioned before and
study centre.
The heterogeneity between studies was estimated by a likelihood ratio test comparing a
model that included the product terms between each study with the variable of interest and a
model without the product terms. When significant heterogeneity between studies was
detected, the pooled OR was also computed by including the study-specific estimates in a
two-stage random effect logistic regression model with the maximum likelihood estimator.
When data were analyzed in strata of covariates, interaction tests between strata were
performed
RESULTS
Table 2 gives the characteristics of cases and controls according to age, sex and other
selected covariates. There was a high predominance of male cases (81%), and cases were
more frequently and heavily exposed to tobacco and alcohol. There were more Latin
Americans among cases and less non Hispanic whites, and cases tended to be less educated
than controls.
Table 3 presents the ORs of HNC according to selected aspects of family history of HNC. A
family history of HNC was reported by 305 (3.6%) cases and 238 (1.8%) controls, and
significantly increased the risk of HNCs (OR=1.68, 95% CI 1.23-2.29). Only 18 cases
(0.23%) and 10 controls (0.09%) reported two or more first degree relatives with HNCs and
the corresponding OR was 2.65 (95% CI 1.13-6.22). Although the OR varied slightly across
strata of sex and age, all point estimates were above unity, and no clear pattern emerged.
The OR was 1.53 for probands with cancer at the oral cavity, 1.55 for oropharynx, 2.28 for
hypopharynx, 1.82 for oral cavity/pharynx not otherwise specified and 2.07 for laryngeal
cancer. Subjects with an affected sibling (OR=2.23, 95% CI 1.61-3.08) had a significantly
(p=0.036) higher risk than subjects with an affected parent (OR=1.45, 95% CI 1.14-1.84).
The risk was somewhat higher for probands aged 50 years or more (OR=1.83, 95% CI
1.47-2.26) than for younger ones (OR=1.38, 95% CI 0.87-2.18), although the difference was
not statistically significant.. Study-specific estimates were significantly heterogeneous for
the overall effect of family history and in a few strata. The random effect estimates,
however, did not differ substantially from the fixed effect ones, although the CIs were wider.
Under the random effect model the OR for family history of HNC was 1.68 (95%
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1.23-2.29). When recalculated excluding each study at a time, the pooled OR ranged
between 1.57 (95% CI 1.19-2.06, excluded study: Milan) and 1.83 (95% CI 1.42-2.36,
excluded study: Houston). Grouping the studies by location did not explain the observed
heterogeneity (data not shown). The results did not materially change when the analysis was
restricted to the cases for which the histology was known to be squamous cell carcinoma.
Figure 1 shows the study specific estimates. The point estimates ranged between 0.82 and
4.08. Only in two out of 12 studies the OR was below unity (Central Europe and Houston).
Table 4 shows the ORs for family history of HNC in strata of tobacco and alcohol
consumption. Light tobacco users where defined as subjects who smoked ≤20 tobacco-years
(combination of packyear of cigarettes and packyear of cigars and pipe in cigarette
equivalent) or subjects who snuffed tobacco only. Heavy tobacco users were subjects who
smoked >20 tobacco-years or subjects who ever chewed tobacco. The ORs were 0.86 (95%
CI 0.48-1.55) in never tobacco users, 3.45 (95% CI 2.19-5.43) in light tobacco users and
1.72 (95% CI 1.32-2.23) in heavy tobacco users. For never, light (≤3 drinks of alcoholic
beverages per day) and heavy (>3 drinks per day) alcohol users the OR were 1.49, 1.63 and
2.02, respectively.
Figure 2 shows the OR of HNC for various combinations of family history of HNC (No/
Yes) and tobacco and alcohol consumption (Never/Ever) relative to subjects with no family
history, and were never users of tobacco and alcohol. Among . never users of alcohol and
tobacco there were 419 cases and 1958 controls without a family history of HNC (reference
category) and 10 cases and 37 controls with family history of HNC. Having a first degree
relative with HNC changed the OR from 1 to 1.30 in never tobacco and alcohol users, from
2.11 to 3.63 in users of tobacco only, from 1.08 to 0.71 in users of alcohol only and from
3.34 to 7.21 in alcohol and tobacco users(p-for interaction <0.0001).
The OR for family history of (non HNC) tobacco related cancers and for other cancers are
presented in Table 5. A weak association was observed for family history of tobacco related
cancers (OR=1.11, 95% CI 1.01-1.23). The association was stronger - or limited to -
probands with laryngeal cancer (OR=1.27, 95% CI 1.09-1.47). When family history of lung
cancer only was considered, the ORs were 1.21 (95% CI 1.04-1.40) for all HNCs, and 1.37
(95% CI 1.10-1.71) for laryngeal cancer (data not shown). No association emerged for
family history of other cancers (OR=0.98, 95% CI 0.89-1.08).
DISCUSSION
In this pooled analysis of case-control studies, a family history of HNCs in first degree
relatives increased the risk of HNCs, and the association appeared stronger for distal HNC
(hypopharynx and larynx). The risk was significantly higher if the affected relative was a
sibling, rather than a parent. The increase in risk was more marked – or limited to – subjects
who had ever used tobacco. The association of HNC risk with family history of other
smoking related cancers was significant, but weak, and no association emerged for all other
cancers.
An elevated risk of HNC in subjects with a history of cancer at the same site has been
reported in other studies, some of which are included in this pooled analysis. Five case
control studies from the United States (US) (12;17), Puerto Rico (18), Brazil (14), and Italy
and Switzerland (20) investigated the risk of HNCs (or of some subsite combination) in
subjects with a family history of HNCs in first degree relatives, relative to those without,
reporting ORs ranging between 1.2 and 3.8. In three record linkage studies from Utah (11),
Norway (16) and Sweden (19), the relatives of HNC cases had standardized incidence ratios
(SIR) of developing HNC that ranged between 1.4 and 8.0. In a study from the Netherlands,
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parents and siblings of HNC cases had a 3.5 times higher risk of developing HNC than the
relatives of proband’s spouses (13). In a Canadian study with a similar design the relative
risk of developing HNC in first degree relatives of HNC cases was 3.8, as compared to
relatives of spouses, and 7.9 when the index case had multiple primary cancers (14), (15).
Although the overall evidence suggests that having an affected first degree relative increases
the risk of HNCs, the point estimates vary widely across studies. This is not surprising, since
only a small proportion of subjects had a family history of HNC, and estimates were often
based on small numbers.
Familial aggregation may indicate that inheritable genetic factors play a role in HNC risk,
but may also reflect a tendency of relatives to have similar alcohol and tobacco behaviors.
Several genetic polymorphisms in genes involved in the metabolism of carcinogens, DNA
repair, or in several other processes have been associated to HNC risk, although results were
not always consistent (36;37).. On the other hand, genetic variants in the alcohol metabolism
genes ADH1B and ADH7 were shown to be associated with head and neck cancer risk in 3
independent populations (38). Given that the differential ability to metabolize carcinogens
matters only when exposure occurs, it is also possible that the familial risk reflects both a
higher genetic susceptibility to HNC together with an aggregation of exposures.
In this analysis, there was significant heterogeneity between studies, which may be related to
different genetic susceptibility in various populations, but also to variable exposure to major
non-genetic risk factors for HNC. Given the different characteristics of the various
populations, including variable exposure to alcohol, tobacco and other environmental
factors, and the different methods used, a degree of heterogeneity across studies is to be
expected. For example, in the Houston study, controls were recruited from hospital visitors,
and individuals with a family history of HNC may have been more willing to participate.
Moreover, the Houston study had the highest proportion of never smokers among the
included studies. These facts may explain a lower estimate of the effect of family history.
It is also possible that the prevalence of susceptibility genes varies in different populations,
as has indeed been observed for some polymorphic genes linked to the metabolism of
carcinogens (39). With only a few exceptions, however, all study estimates were above
unity, and sensitivity analysis showed that results were not strongly driven by any single
study. The two studies for which the point estimate was below one were from central Europe
and Houston (Texas, US) and did not identify a clear geographic or ethnic pattern. In fact,
the location of the studies did not explain the heterogeneity between studies. Despite a
certain degree of heterogeneity between studies, however, it is reassuring that the results
were similar when fixed or random effect models were used. In many of the studies included
in this analysis, family history of cancer was self-reported, in the absence of any other
verification. Moreover, all the studies included in this pooled analysis had a case-control
design, and were thus prone to reporting bias. It is possible that cases were more sensitized
to the issue, and a differential recall of cancers in the family occurred. On the other hand, in
the Tampa study, controls were recruited through a screening center, and may have been
more health conscious than the general population.
The three record linkage studies that investigated the issue found risks above unity: In the
Swedish Family Cancer Database the standardized incidence ratio (SIR) of HNC was 1.4
(95% CI 0.98-2.0) in offspring of subjects with HNC in a record linkage study based on the
Norwegian Cancer Registry the SIR of HNCs below age 45 years was 1.9 (95% 0.9-3-5) in
those with a family history of lung or HNC, and in a study based on the Utah Population
Database, the SIR of oral and laryngeal cancer were, respectively, 1.8 (95% CI 0.5-4.0) and
8.0 (95% CI 2.1-17.9) in subjects with a family history of cancers at the same sites.
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Notwithstanding the difficulties in comparing these results, based on different aggregations
of cancer sites and age groups, to our data, there is no indication that studies not relying on
self-reported family history or on a case-control design showed a systematic tendency
towards estimating lower risks.
For many cancer sites the risk is increased in those with a family history of cancer at that
site (40), and it is not surprising if this is true for HNCs too. In our study, the OR was higher
when the proband had a more distal HNC cancer, i.e. at the hypopharynx or larynx. The few
other studies available also suggest that familial risk may be stronger for distal HNC. A
case-control study from the US on 1,114 cases of oral and pharyngeal cancer (12) found
odds ratios (OR) of 1.2 (95% confidence interval, CI, 0.7-2.3) and 1.6 (0.7-3.8) in subjects
reporting family history of oral/pharyngeal and laryngeal/esophageal cancer, respectively. In
the Utah population database (11), the SIR of laryngeal cancer in subjects with a family
history of laryngeal cancer (SIR=8.0) was higher than that of oral/pharyngeal cancer
associated with a family history of cancer at the same sites (SIR=1.8). In the case-control
study (956 cases and 2362 controls) of oral and pharyngeal cancer from Italy and
Switzerland included in this pooled analysis, the multivariate ORs were 2.6 for a family
history of oral cancer, and 3.8 for family history of laryngeal cancer (20).
In this pooled analysis, the OR was slightly but significantly higher when the affected
relative was a sibling, rather than a parent. In a study conducted in the Netherlands (13) on a
retrospective cohort of first degree relatives of patients with HNC and of the patients’
spouses, the OR of HNC was 1.9 (95% CI 0.9-3.8) for parents and 14.6 (3.1-69) for siblings.
Similarly, in a case-control study conducted in Brazil (14) on 754 cases of HNCs the OR
was 2.5 (95% CI 1.0-6.0) for a family history of HNC in the father and 8.6 (95% CI 2.7-27)
if the affected relative was a sibling. In a case-control study from Puerto Rico (18), based on
342 oral/pharyngeal cases and included in the present collaborative analysis, the OR was 2.0
for history of esophageal or HNC in a parent and 2.7 in a sibling. In a study from Italy and
Switzerland (20) the OR of oral/pharyngeal cancer in subjects with a parent or a sibling with
HNC were, respectively, 2.6 and 3.4. Taken together, the epidemiologic evidence
consistently indicates that the risk is higher if the affected relative is a sibling. This may also
explain the slightly lower SIR estimated in the Swedish Family Cancer Database (19), where
only parents and offspring were considered, as compared to other studies. The higher risk
associated with a history of HNC in a sibling suggests a recessive mode of inheritance of
HNC susceptibility. An alternative explanation may be that siblings share more
environmental exposures than children do with their parents.
When we investigated the effect of family history in combination with alcohol and tobacco
use, the risk associated with family history appeared stronger in – or limited to - subjects
exposed to tobacco. The joint effect of these three factors has been considered in two case-
control studies (18), (20), both included in the present pooled analysis. In the study from
Puerto Rico (18), the addition of family history increased the risk at least two-fold in all
combinations of tobacco and alcohol use, but the risks appeared somewhat higher in subjects
more heavily exposed. In the case-control from Italy and Switzerland, the risk appeared
stronger for subjects more heavily exposed to tobacco (20). In those two studies, however,
the limited sample size did not allow for setting the reference category to non-alcohol and
non-tobacco users. Even in this combined reanalysis the standard errors of the estimates
were large, given the rarity of family history of HNC and of cases of HNC not exposed to
alcohol and tobacco. Thus, this subgroup analysis should be considered with caution. An
interpretation of this result is that what is inherited is the susceptibility to the damage caused
by tobacco. In the absence of tobacco exposure, subjects inheriting the predisposition do not
show an increased risk of HNC. If this were true, the best way of avoiding HNC would be
avoiding alcohol and, most of all, tobacco exposure, particularly in subjects with a family
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history of the disease. Information on the tobacco and alcohol exposure of the relatives
would provide further insight on this issue. Unfortunately, these data were not available in
the studies considered.
An Italian study calculated that, even in smokers who had stopped smoking around 50 years
of age, the excess risk of HNC by age 75 years (as compared to never smoking) was
approximately halved in comparison with continuing smoking (41). Thus, stopping smoking
is an effective measure to reduce HNC cancer risk. For some cancer sites, the risk associated
with family history is higher at younger ages (40). In our study the point estimate was higher
in older subjects, although the interaction of family history of HNC with age was not
significant. It is possible that a differential contribution of the various studies to the age-
specific groups may have obscured a relation with age. On the other hand, if familial
susceptibility to HNC is mediated by the exposure to tobacco, which generally starts in the
late second decade of life, it is conceivable that the age-distribution of familial HNC differs
from that of other cancers. We found a small but significant increased risk of HNC, and
particularly laryngeal cancer, in subjects with a family history of tobacco-related cancers. It
is conceivable that an inherited susceptibility to the damage of tobacco affects the risk of all
or most tobacco-related neoplasms, though, as for HNC, familial aggregation may reflect
similar attitudes towards tobacco consumption.
The percent attributable risk (PAR) to family history is low in the overall dataset, i.e. on the
order of 1 to 2%, even for more distal sites or when the affected relative is a sibling.
However, this does not necessarily imply that the influence of susceptibility is low assuming
that high risk alleles show high frequency and low penetrance (10). Furthermore, the PAR is
population-dependent and hence influenced by the population mix considered in this pooled
analysis. .
Acknowledgments
This work was supported by a grant from the US National Institutes of Health, National Cancer Institute (R03
CA113157). The study sponsors had no role in the design of the study; the collection, analysis, or interpretation of
the data; the writing of the manuscript; or the decision to submit the manuscript for publication.
The individual studies were funded by the following grants: Milan study: Italian Association for Research on
Cancer (AIRC); Aviano and Italy Multicenter studies: Italian Association for Research on Cancer (AIRC), Italian
League Against Cancer, Italian Ministry of Research; Swiss study: Swiss League against Cancer and the Swiss
Research against Cancer/Oncosuisse (KFS-700 and OCS-1633); Central Europe study: World Cancer Research
Fund and the European Commission’s INCO-COPERNICUS Program (Contract No. IC15-CT98-0332); North
Carolina study: NIH grant R01CA61188 and in part by a grant from the National Institute of Environmental Health
Sciences (P30ES010126); Tampa study: US NIH P01CA068384 and K07CA104231; Los Angeles study: National
Institute of Health (P50CA90388, R01DA11386, R03CA77954, T32CA09142, U01CA96134, and R21ES011667)
as well as the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer
Center; Houston study: US NIH R01ES11740 and R01CA100264; South America study: FONCYT (Fondo para la
Investigacion Cientifica y Tecnologica) Argentina, IMIM (Barcelona), Fundação de Amparo á Pesquisa no Estado
de São Paulo (FAPESP) No 01/01768-2, European Commission (IC18-CT97-0222); IARC Multicenter study:
Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government (FIS 97/0024, FIS 97/0662, and BAE
01/5013), International Union Against Cancer (UICC), Yamagiwa-Yoshida Memorial International Cancer Study
Grant;
Reference List
(1). Ferlay, J.; Bray, F.; Pisani, P.; Parkin, DM. Cancer Incidence, Mortality and Prevalence
Worldwide. IARC Press; Lyon: 2004. GLOBOCAN 2002. IARC CancerBase No.5.
(2). La Vecchia C, Lucchini F, Negri E, Levi F. Trends in oral cancer mortality in Europe. Oral Oncol.
Apr; 2004 40(4):433–9. [PubMed: 14969823]
(3). Bosetti C, Garavello W, Levi F, Lucchini F, Negri E, LaVecchia C. Trends in laryngeal cancer
mortality in Int. Europe J Cancer. Aug 1; 2006 119(3):673–81.
Negri et al. Page 8
Int J Cancer. Author manuscript; available in PMC 2013 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(4). Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt
AW, Fabianova E, Wunsch-Filho V, Franceschi S, Hayes RB, et al. Alcohol drinking in never
users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer:
pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl
Cancer Inst. May 16; 2007 99(10):777–89. [PubMed: 17505073]
(5). Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L,
Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and
pharyngeal cancer. Cancer Res. Jun 1; 1988 48(11):3282–7. [PubMed: 3365707]
(6). Negri E, Franceschi S, Tavani A. Attributable risk for oral cancer in northern Italy. Cancer
Epidemiol Biomarkers Prev. May; 1993 2(3):189–93. [PubMed: 8318870]
(7). Harty LC, Caporaso NE, Hayes RB, Winn DM, Bravo-Otero E, Blot WJ, Kleinman DV, Brown
LM, Armenian HK, Fraumeni JF Jr. Shields PG. Alcohol dehydrogenase 3 genotype and risk of
oral cavity and pharyngeal cancers. J Natl Cancer Inst. Nov 19; 1997 89(22):1698–705.
[PubMed: 9390539]
(8). De Andrade M, Amos CI, Foulkes WD. Segregation analysis of squamous cell carcinoma of the
head and neck: evidence for a major gene determining risk. Ann Hum Genet. Nov; 1998 62(Pt 6):
505–10. [PubMed: 10363128]
(9). Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1
polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol
Biomarkers Prev. Feb; 2000 9(2):185–91. [PubMed: 10698480]
(10). Peto J, Houlston RS. Genetics and the common cancers. Eur J Cancer. Oct; 2001 37(Suppl
8):S88–S96. [PubMed: 11602375]
(11). Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based
assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. Nov 2;
1994 86(21):1600–8. [PubMed: 7932824]
(12). Goldstein AM, Blot WJ, Greenberg RS, Schoenberg JB, Austin DF, Preston-Martin S, Winn DM,
Bernstein L, McLaughlin JK, Fraumeni JF Jr. Familial risk in oral and pharyngeal cancer. Eur J
Cancer B Oral Oncol. Sep; 1994 30B(5):319–22. [PubMed: 7703800]
(13). Copper MP, Jovanovic A, Nauta JJ, Braakhuis BJ, de Vries N, van der Waal I, Snow GB. Role of
genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch
Otolaryngol Head Neck Surg. Feb; 1995 121(2):157–60. [PubMed: 7840922]
(14). Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL. Family history of cancer is a risk
factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. Int J
Cancer. Dec 11; 1995 63(6):769–73. [PubMed: 8847131]
(15). Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous
cell carcinoma of the head and neck: retrospective case-control study. BMJ. Sep 21; 1996
313(7059):716–21. [PubMed: 8819440]
(16). Mork J, Moller B, Glattre E. Familial risk in head and neck squamous cell carcinoma diagnosed
before the age of 45: a population-based study. Oral Oncol. Jul; 1999 35(4):360–7. [PubMed:
10645399]
(17). Yu GP, Zhang ZF, Hsu TC, Spitz MR, Schantz SP. Family history of cancer, mutagen sensitivity,
and increased risk of head and neck cancer. Cancer Lett. Nov 1; 1999 146(1):93–101. [PubMed:
10656614]
(18). Brown LM, Gridley G, Diehl SR, Winn DM, Harty LC, Otero EB, Fraumeni JF Jr. Hayes RB.
Family cancer history and susceptibility to oral carcinoma in Puerto Rico. Cancer. Oct 15; 2001
92(8):2102–8. [PubMed: 11596026]
(19). Li X, Hemminki K. Familial upper aerodigestive tract cancers: incidence trends, familial
clustering and subsequent cancers. Oral Oncol. Apr; 2003 39(3):232–9. [PubMed: 12618195]
(20). Garavello W, Foschi R, Talamini R, La Vecchia C, Rossi M, Dal Maso L, Tavani A, Levi F,
Barzan L, Ramazzotti V, Franceschi S, Negri E. Family history and the risk of oral and
pharyngeal cancer. Int J Cancer. 2007 In Press.
(21). Franceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E, Serraino D, La Vecchia C.
Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in
northern Italy. Cancer Res. Oct 15; 1990 50(20):6502–7. [PubMed: 2208109]
Negri et al. Page 9
Int J Cancer. Author manuscript; available in PMC 2013 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(22). Baron AE, Franceschi S, Barra S, Talamini R, La Vecchia C. A comparison of the joint effects of
alcohol and smoking on the risk of cancer across sites in the upper aerodigestive tract. Cancer
Epidemiol Biomarkers Prev. Nov; 1993 2(6):519–23. [PubMed: 8268767]
(23). Bosetti C, Gallus S, Trichopoulou A, Talamini R, Franceschi S, Negri E, La Vecchia C. Influence
of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer
Epidemiol Biomarkers Prev. Oct; 2003 12(10):1091–4. [PubMed: 14578148]
(24). Levi F, Pasche C, Lucchini F, Franceschi S, Monnier P. Food groups and risk of oral and
pharyngeal cancer. Int J Cancer. Aug 31; 1998 77(5):705–9. [PubMed: 9688303]
(25). Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Janout V,
Fabianova E, Bencko V, Moullan N, Chabrier A, Hung R, et al. Evidence for an important role of
alcohol- and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. Cancer
Epidemiol Biomarkers Prev. Apr; 2006 15(4):696–703. [PubMed: 16614111]
(26). Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P. The human OGG1 DNA repair
enzyme and its association with orolaryngeal cancer risk. Carcinogenesis. Jul; 2002 23(7):1229–
34. [PubMed: 12117782]
(27). Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao J, Cao W, Cozen W, Mack TM, Zhang
ZF. Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and
squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer. Feb 1; 2006
118(3):714–20. [PubMed: 16094634]
(28). Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of methionine synthase
and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a
case-control analysis. Cancer Epidemiol Biomarkers Prev. May; 2005 14(5):1188–93. [PubMed:
15894670]
(29). Hayes RB, Bravo-Otero E, Kleinman DV, Brown LM, Fraumeni JF Jr. Harty LC, Winn DM.
Tobacco and alcohol use and oral cancer in Puerto Rico. Cancer Causes Control. Feb; 1999
10(1):27–33. [PubMed: 10334639]
(30). Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H,
Rose B, Pintos J, Fernandez L, Idris A, et al. Human papillomavirus and oral cancer: the
International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. Dec 3; 2003
95(23):1772–83. [PubMed: 14652239]
(31). Sun EC, Curtis R, Melbye M, Goedert JJ. Salivary gland cancer in the United States. Cancer
Epidemiol Biomarkers Prev. Dec; 1999 8(12):1095–100. [PubMed: 10613342]
(32). Yu, MC.; Yuan, JM. Nasopharyngeal cancer. In: Schottenfeld, David; Fraumeni, Joseph.F.,
editors. Cancer Epidemiology and Prevention. 3rd edition ed. Oxford University Press; Oxford:
2006.
(33). IARC working group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and
involuntary smoking. IARC Press; Lyon: 2004.
(34). Rubin, D. Multiple imputation for nonresponse in survey. John Wiley and Sons, Inc.; New York:
1987.
(35). Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-
control studies. IARC Sci Publ. 1980; (32):5–338.
(36). Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, Oude Ophuis MB,
Benhamou S, Foulkes WD, Katoh T, Coutelle C, Romkes M, et al. Meta- and pooled analyses of
GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer
Epidemiol Biomarkers Prev. Dec; 2003 12(12):1509–17. [PubMed: 14693745]
(37). Hung RJ, van der HO, Tavtigian SV, Brennan P, Boffetta P, Hashibe M. Perspectives on the
molecular epidemiology of aerodigestive tract cancers. Mutat Res. Dec; 2005 30;592(1-2):102–
18.
(38). Hashibe M, McKay JD, Curado MP, Oliveria JC, Koifman S, Koifman R, Zaridze D, Shangina
O, Wunsch-Filho V, Eluf-Neto J, Levi JE, Matos E, et al. Multiple ADH genes are associated
with upper aerodigestive cancers. Advanced online publication (2008 ed). May 25.2008
(39). Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum
L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, et al. Metabolic gene polymorphism
Negri et al. Page 10
Int J Cancer. Author manuscript; available in PMC 2013 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
frequencies in control populations. Cancer Epidemiol Biomarkers Prev. Dec; 2001 10(12):1239–
48. [PubMed: 11751440]
(40). Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene. Aug
23; 2004 23(38):6471–6. [PubMed: 15322517]
(41). Bosetti C, Gallus S, Peto R, Negri E, Talamini R, Tavani A, Franceschi S, La VC. Tobacco
smoking, smoking cessation, and cumulative risk of upper aerodigestive tract cancers. Am J
Epidemiol. Feb 15; 2008 167(4):468–73. [PubMed: 18056925]
Negri et al. Page 11
Int J Cancer. Author manuscript; available in PMC 2013 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Study specific estimates of the odds ratio (OR) of head and neck cancer (HNC) in subjects
with a family history of HNC in first degree relatives. Squares = study-specific odds ratios;
size of the square = the weight given to this study (inverse of the variance of the log odds
ratio) when estimating the summary odds ratio; horizontal lines = study-specific confidence
intervals (CIs); diamond = summary estimate combining the study-specific estimates with a
random-effects model; solid vertical line = odds ratio of 1; dashed vertical line = summary
odds ratio.
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Figure 2.
Interaction between smoking and drinking habits and family history of head and neck cancer
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Table 1
Summary of individual studies in INHANCE pooled data v1.0, by region and study period
Study Location Recruitment
period
Cases Controls2
Source Participation
rate
Age
eligibility
Number Source Participation
rate
Number
Europe
Milan, Italy 1984-1989 Hospital 95%3 <80 416 Hospital - unhealthy 95%3 1531
Aviano, Italy 1984-1989 Hospital >95%3 >18 482 Hospital - unhealthy 95%3 855
Italy (Aviano, Milan,
Latina)4
1990-1999 Hospital >95% 18-80 1058 Hospital - unhealthy 95% 2579
Switzerland 1991-1997 Hospital 95% <80 516 Hospital - unhealthy 95% 883
Central Europe
(Banska Bystrica,
Bucharest, Budapest,
Lodz,
Moscow)4
1998-2003 Hospital 96% ≥15 762 Hospital - unhealthy 97% 907
North America
North Carolina 1994-1997 Hospital 88% >17 180 Hospital – unhealthy 86% 202
Tampa, FL 1994-2003 Hospital 98% ≥18 207 Cancer screening
clinic - healthy
90% 897
Los Angeles, CA 1999-2004 Cancer registry 49% 18-65 417 Neighborhood 67.5% 1005
Houston, TX 2001-2006 Hospital 95% ≥18 829 Hospital visitors >80% 865
South/Central America
Puerto Rico 1992-1995 Cancer registry 71% 21-79 350 Residential records 83% 521
South America
(Buenos Aires,
Havana, Goiãnia,
Pelotas, Porto Alegre,
Rio de Janeiro, São
Paolo) 5
2000-2003 Hospital 95% 15-79 2191 Hospital - unhealthy 86% 1706
International
International (Italy,
Spain, Ireland, Poland,
Canada, Australia,
Cuba,
India, Sudan) 4
1992-1997 Hospital 88.7 na 1559 Hospital/Community 87.3 1676
1
Representative publication in which study methods are available.
2All studies frequency matched controls to cases, minimally on age and sex. Additional frequency matching factors included center (Italy, Central
Europe, South America and International multicenter studies), ethnicity (Tampa, Los Angeles studies), neighborhood (Los Angeles study).
3
Participation rate not formally assessed, estimated response rate reported.
4
Multicenter study
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Table 2
Demographic characteristics of 8967 cases and 13627 controls included in the pooled analysis
Demographic
characteristics Cases (%) Controls (%)
Age
 <40 323 3.6 892 6.6
 40-<45 533 5.9 1039 7.6
 45-<50 1012 11.3 1587 11.7
 50-<55 1415 15.8 2181 16.0
 55-<60 1665 18.6 2353 17.3
 60-<65 1480 16.5 2088 15.3
 65-<70 1243 13.9 1734 12.7
 70-<75 837 9.3 1232 9.0
 >=75 459 5.1 521 3.8
Sex
 Men 7248 80.8 9794 71.9
 Women 1719 19.2 3833 28.1
 Χ2 test <0.0001b
Race/Ethnicity 1
 Non hispanic white 5560 62.0 10332 75.8
 Black 341 3.8 454 3.3
 Hispanic/Latino 141 1.6 329 2.4
 Asian/Pacific islanders 616 6.9 654 4.8
 Latin Americans 2191 24.4 1706 12.5
 Others 118 1.3 152 1.1
 Χ2 test <0.0001
Education
 None 446 5.0 304 2.2
 <Junior high school 4383 48.9 6240 45.8
 Some high school 1126 12.6 1521 11.2
 High school graduate 1022 11.4 1502 11.0
 Vocational, some college 831 9.3 1758 12.9
 >=College 833 9.3 2051 15.1
 Missing 326 3.6 251 1.8
 Χ2 test <0.0001
Tobacco smoking
 Never# 913 10.2 5298 38.9
 ever 8051 89.8 8320 61.1
 Missing 3 9
 Χ2 test <0.0001
Packyears
 non cigarette smokers 1322 14.9 5489 40.8
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Demographic
characteristics Cases (%) Controls (%)
 1-10 py 632 7.1 2032 15.1
 11-20 py 910 10.3 1607 11.9
 21-30 py 1270 14.3 1358 10.1
 31-40 py 1366 15.4 1084 8.1
 41-50 py 1072 12.1 722 5.4
 >50 py 2300 25.9 1183 8.8
 Missing 95 152
 Χ2 test <0.0001
Alcohol drinking
 never 1435 16.0 3653 26.8
 ever 7521 84.0 9967 73.2
 Missing 11 7
 Χ2 test <0.0001
Frequency of drinking 1
 never drinker 1435 16.0 3653 26.8
 <1drink per day 1286 14.4 3000 22.0
 1-2 drinks per day 1459 16.3 2920 21.4
 3-4 drinks per day 1030 11.5 1560 11.5
 5-6 drinks per day 807 9.0 784 5.8
 >=7 drinks per day 2597 29.0 1343 9.9
 Missing 353 3.9 367 2.7
 Χ2 test <0.0001
HNC subtype
 Oral cavity 2332 26.0
 Oroharynx 668 7.4
 Hypopharynx 2254 25.1
 Oral/Pharynx NOS 835 9.3
 Larynx 2572 28.7
 Overlapping HNC 306 3.4
#Never tobacco users were subjects that never used cigarette, pipe, cigar, snuff or chew.
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Table 3
Family history of head and neck (oral cavity/pharynx/larynx) cancers (HNC) in first degree relatives and risk
of HNC according to selected probands’ or relatives’ characteristics
Family history of HNC
No Yes
Cases Controls Cases Controls OR# (95% CI) p forheterogeneity§ OR
* 95%CI
All subjects 8134 12741 305 238 1.75 (1.44, 2.12) 0.02 1.68 (1.23, 2.29)
No of affected relative ~ 0.17
1 7742 11271 274 217 1.62 (1.32, 1.98)
≥2 18 10 2.65 (1.13, 6.22)
Probands’sex
Male 6552 9098 249 172 1.73 (1.39, 2.15) 0.07
Female 1582 3643 56 66 1.70 (1.10, 2.61) 0.06
Probands’ age
<50 years 1751 3308 45 48 1.38 (0.87, 2.18) 0.04 1.43 (0.63, 3.21)
≥50 years 6383 9433 260 190 1.83 (1.47, 2.26) 0.07
Probands’ cancer site
Oral cavity 2085 12741 66 238 1.53 (1.11, 2.11) 0.11
Oropharynx 2069 12741 80 238 1.55 (1.16, 2.07) 0.03 1.72 (1.09, 2.70)
Hypopharynx 603 11230 28 217 2.28 (1.46, 3.54) 0.69
Oral cavity/pharynx NOS 743 12741 22 238 1.82 (1.13, 2.92) 0.08
Larynx 2357 10758 107 205 2.07 (1.57, 2.73) 0.15
Overlapping 277 3116 2 48
Type of affected relative
Parents 8134 12741 178 157 1.45 (1.14, 1.84) 0.04 1.37 (0.96, 1.94)
siblings 121 72 2.23 (1.61, 3.08) 0.03 2.06 (1.23, 3.45)
Sex of affected relative
Male 8134 12741 189 126 1.98 (1.54, 2.55) 0.20
Female 85 70 1.40 (0.98,2.02) 0.22
#Odds ratio for family history (yes vs no) were adjusted on age (categorical), sex race, education level ,centers, packyear, drinks per day
(continuous) number of sisters, number of brothers, duration of pipe use and duration of cigar use, chew status and snuff status
§
Between studies
*
Random effect estimates
~
Does not include Milan
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Table 4
Family history of Head and Neck (oral cavity/pharynx/larynx) cancers (HNC) in first degree relatives and risk
of HNC
Family history of head and neck cancer
No Yes 95% CI
Cases Controls Cases Controls OR p for heterogeneity§ OR* 95%CI
Tobacco consumption a
Never tobacco users# 818 4803 15 89 0.86 (0.48, 1.55) 0.60
Light tobacco users# 1291 3204 53 38 3.45 (2.19, 5.43) 0.36
Heavy tobacco users# 5308 3888 223 93 1.72 (1.32, 2.23) 0.03 1.52 (1.10, 2.10)
Alcohol consumption b
Never drinkers~ 1367 3480 40 61 1.49 (0.95, 2.36) 0.08
Light drinkers~ 2125 5090 60 83 1.63 (1.11, 2.38) 0.24
Heavy drinkers~ 3925 3340 191 76 2.02 (1.50, 2.72) 0.03 1.84 (1.28, 2.65)
§
Between studies
*
Random effect estimates
a
Light tobacco users where defined as subjects who smoked ≤20 tobacco-years (combination of packyear of cigarettes and packyear of cigars and
pipe in cigarette equivalent) or subjects who snuffed tobacco only. Heavy tobacco users were subjects who smoked >20 tobacco-years or subjects
who ever chewed tobacco.
#
adjusted on age (categorical) , sex, race, education level, centers, number of drinks per day, number of sisters, number of brothers (continuous)
b
Light drinkers were defined as subjects who drank ≤3 drinks of alcoholic beverages per day, and heavy drinkers >3 drinks per day.
~
adjusted on age (categorical) , sex, race, education level, centers, packyear (continuous), duration of pipe use (continuous), duration of cigar use
(continuous), number of sisters, number of brothers, chew status and snuff status
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Table 5
Family history of (non HNC) smoking related1 and other cancers in first degree and risk of Head and Neck
cancers (HNC)
Family history of HNC
No Yes *
Cases Controls Cases Controls OR# 95% CI p for heterogeneity§ OR* 95%CI
Family history of (non
HNC) smoking-related
cancer1
All subjects 6973 10067 1061 1431 1.11 (1.01, 1.23) 0.36
Probands’ age
<50 years 1559 2652 183 273 1.17 (0.93, 1.47) 0.77
50≥ years 5414 7415 878 1158 1.10 (0.98, 1.22) 0.30
Proband’ cancer site
Oral cavity 1876 10067 232 1431 1.10 (0.92, 1.30) 0.94
Oropharynx 1806 10067 309 1431 1.15 (0.99, 1.34) 0.56
Hypopharynx 537 8631 67 1335 0.98 (0.73, 1.31) 0.16
Oral cavity/pharynx NOS 629 10067 72 1431 0.93 (0.71, 1.22) 0.21
Larynx 1853 8149 374 1333 1.27 (1.09, 1.47) 0.2
Overlapping 272 2902 7 262
Family history of other
cancer
All subjects 6813 9632 1221 1866 0.98 (0.89, 1.08) 0.18
Probands’ age
<50 years 1517 2513 225 412 0.92 (0.75, 1.14) 0.32
50≥ years 5296 7119 996 1454 0.98 (0.88, 1.10) 0.02 0.91 (0.72, 1.15)
Proband’ cancer site
Oral cavity 1822 9632 286 1866 0.93 (0.79, 1.10) 0.21
Oropharynx 1728 9632 387 1866 0.93 (0.81, 1.08) 0.54
Hypopharynx 548 8259 56 1707 0.82 (0.59, 1.13) 0.09
Oral cavity/pharynx NOS 589 9632 112 1866 0.96 (0.75, 1.22) 0.94
Larynx 1859 7810 368 1672 1.10 (0.95, 1.29) 0.39
Overlapping 267 2811 12 353
#Odds ratio for family history yes vs no, adjusted on age (categorical), sex race, education level ,center, packyears of cigarettes, drinks per day
(continuous) number of sister, number of brothers, duration of pipe use and duration of cigar use, chew status, snuff status.
§
Between studies
*
Random effect estimates
1
Includes cancers of the lung, nasopharynx, nasal cavity, paranasal sinuses, esophagus, stomach, pancreas, liver, kidney (body and pelvis), urinary
bladder, uterine cervix and bone marrow (myeloid leukemia)
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